Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

atebimetinib (IMM-1-104)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Immuneering

Drug class:

MEK1 inhibitor, MEK2 inhibitor

Related drugs:

NRAS mutation	Melanoma	NRAS mutation	Melanoma	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
BRAF mutation	Melanoma	BRAF mutation	Melanoma	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D	sotorasib + IMM-1-104 Sensitive: D – Preclinical sotorasib + IMM-1-104 Sensitive : D